S (NVO)

Executive Summary

Novo Nordisk is the Danish pharmaceutical company that originated the modern GLP-1 receptor agonist category — and that, eighteen months after trading at all-time highs above $148 ADR, has been ground down approximately 56 percent to today’s $44.55 by a sequence of competitive disappointments, a failed CagriSema phase 3 read, an unscheduled CEO transition, and a FY2026 guide for adjusted sales contraction. This is the deepest value setup we have ever seen on this franchise. The question is whether the bear case is now fully priced in — and whether the Wegovy oral-pill launch (a clinical bright spot) is the inflection the bull case requires. The Q1 2026 print published May 6 contained both bad news and good news, as is typical of mid-restructuring stories.

What’s Inside The Full Report

• 15-year financial summary table — revenue, net income, GAAP & adjusted EPS
• Valuation framework — current multiples vs. 5-year historical range
• Peer comparison table — multiples, margins, balance-sheet metrics
• Base case, bull case, bear case price targets with explicit math
• Competitive position and economic moat analysis
• Management and capital allocation track record
• Balance sheet review — leverage, credit ratings, distribution coverage
• Insider activity — recent open-market buys / sells with interpretation
• Strategic acquisitions and divestitures history
• Sell-side consensus and where TTCM differs
• Detailed risk factors specific to the name
• Bull case and forward catalysts to watch
• TTCM rating with explicit ADD / TRIM price triggers